ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TF/Exatecan Antibody-drug Conjugate STRO-004

Its studies are mostly in Esophageal Neoplasms, led by Sutro Biopharma.

Furthest: phase 1, since Nov 7, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sutro Biopharma11 open or runningphase 1since Nov 7, 2025Nov 7, 2025Dec 2027phase 1 · NCT07227168

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2025First study: phase 1 study in Esophageal NeoplasmsFirst studyNCT07227168 · 200 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 1 study in Esophageal NeoplasmsNCT07227168

TargetBeta

F3 →read by rule
“An antibody-drug conjugate (ADC) composed of a Fc-silent high affinity immunoglobulin G1 (IgG1) monoclonal antibody directed against human tissue factor (TF; F3; coagulation factor III; thromboplastin; CD142) site-specifically ”NCIt, by rule

Other programs on F3

ProgramCompanyFurthest phaseStudies
tisotumab vedotinrulePfizerphase 411
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 33
Anti-TF Antibody-drug Conjugate MRG004Arulelepu-biopharma-co-ltdphase 32
SHR-4375Jiangsu HengRui Medicinephase 22
Anti-TF/TOP1i Antibody-drug Conjugate XB371ruleExelixisphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07227168Esophageal Neoplasms · United States1RecruitingDec 2027200

How it is read

Names in the registry

  • “STRO-004”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.